header logo image


Page 27«..1020..26272829..40..»

Archive for the ‘Death by Stem Cells’ Category

Macchiarini’s seventh transplant patient dies – The Local Italy

Tuesday, March 21st, 2017

Italian surgeon Paolo Macchiarini. Photo: AP Photo/Lorenzo Galassi

A seventh patient of Italian surgeon Paolo Macchiarini, who was fired from a Swedish university over accusations of misconduct, has died.

Macchiarini performed two synthetic trachea transplants on Yesim Cetir, 26, in Stockholm in 2012 and 2013, but she suffered brutal complications until her death.

In the early hours of Monday, her father Hayrullah Cetir announced on his Facebook account that Yesim died at Temple University Hospital in Philadelphia.

"My daughter Yesim died tonight [Sunday] at 9.15pm may she rest in peace," he wrote, publishing a picture of her in a hospital bed.

Macchiarini operated on eight patients between 2011 and 2014, three of them at the prestigious Stockholm-based Karolinska Institute, which selects the winners of the Nobel Prize in medicine.

Only one of the patients survived after having a synthetic trachea, designed and implanted by Macchiarini, removed during a surgery in Russia in 2014.

Cetir was the victim of two failed surgeries as her trachea was first badly damaged during treatment in Turkey before she received surgery in Stockholm.

She went to the United States to receive a trachea from a donor, without being able to recover.

"It is with great sorrow that I offer my sincere condolences to Yesim Cetir's family after having heard about her death. It would of course be inappropriate to discuss her earlier medical condition and treatment," Macchiarini said in a written comment to Swedish public broadcaster SVT.

The surgeon gained worldwide fame in 2011 by carrying out the world's first graft of an artificial plastic trachea, which was to be colonized by the patients' stem cells.

While he said in the medical journal The Lancet that the technique was working, successive deaths of his patients and falsifications in the article led him to be sacked.

Macchiarini was suspected of having embellished his resume to be hired by the Karolinska Institute. He is being investigated by Swedish police.

The scandal hit the Nobel Prize and caused several resignations within the institute.

Continue reading here:
Macchiarini's seventh transplant patient dies - The Local Italy

Read More...

Jailed Iranian researcher’s health worsening rapidly – Nature.com

Tuesday, March 21st, 2017

Courtesy of Vida Mehrannia

Ahmadreza Djalali, a researcher in disaster medicine, was arrested in Tehran in April 2016.

An Iranian researcher jailed in Tehran for the last 11 months is in declining health after spending more than two months on hunger strike. This month, researchers around the world made urgent appeals for his release.

Ahmadreza Djalali, a researcher in disaster medicine and a resident of Sweden, was arrested on an academic visit to Tehran in April 2016. On 11 March he was brought to a prison hospital after he refused to eat in protest at being threatened with the death sentence and at being denied his choice of lawyer. Djalali, who still awaits trial, has experienced kidney and heart pain and for a week in late February refused to take liquids, says his wife, Vida Merhannia. He has lost 30% of his body weight since he entered prison.

Djalali, 45, works on improving hospitals emergency responses to armed terrorism and radiological, chemical and biological threats. He has affiliations with Swedens Karolinska Institute in Stockholm and Italys University of Eastern Piedmont in Novara. But on 25 April 2016 he was arrested and accused of collaboration with a hostile government. According to his wife, he was kept in solitary confinement for three months, and forced to sign a confession.

Djalali began a first hunger strike in late December in protest against what he has told his wife is a false accusation. In late January, a judge on Irans revolutionary court threatened him with a death sentence. He stopped his strike on 15 February, but resumed it three days later after the judge ordered him to change his lawyer or choose a court-appointed one. His trial has not yet been scheduled.

On 9 March, Djalalis colleagues, together with the Committee of Concerned Scientists in New York and human-rights groups such as Amnesty International and Scholars at Risk, wrote to the Iranian authorities to ask that Djalali be given due legal process and released, unless charged with a recognizable criminal offence.

Djalalis case has drawn particular attention in Italy, in part because of his Eastern Piedmont connections. Parliamentarians there have protested to the Iranian ambassador, and Elena Cattaneo, a senator and stem-cell researchers at the University of Milan, said she would refuse to attend a July conference on stems cells in Iran in protest.

Its unclear why the Iranian government has arrested Djalali, says his colleague Luca Ragazzoni, a health researcher at the University of Eastern Piedmont, who worked with him from 2012 to 2015. In a separate case, physicist Omid Kokabee released from a Tehran jail in August 2016 after five years imprisonment believes he himself was punished for refusing to help a covert nuclear-weapons programme. But Ragazzoni says that disaster health research is less controversial. The data we work with are not sensitive, and we publish all our results: I dont see what else a government should be interested in, he says. He thinks the groups international collaborations may have raised suspicion.

The USIran nuclear deal in 2015 had sparked hopes of greater academic freedom in Iran. But since that agreement, other researchers besides Djalali have been imprisoned or sentenced. They include Homa Hoodfar, a CanadianIranian social anthropologist who was arrested in March 2016 and charged with dabbling in feminism and security matters, before being released on humanitarian grounds 112 days later; and retired Iranian polymer scientist Mohammad Hossein Rafiee-Fanood, who was sentenced to six years in prison in May 2015 for political activism, and was released on medical furlough last year.

Hamid Babaei, an Iranian mathematics student who was studying for a PhD in finance at the University of Lige in Belgium when he was arrested in August 2013, remains in prison on a six-year sentence for spying and contact with enemy states. He says that he was imprisoned for refusing to be an informant in Belgium for Irans intelligence ministry.

"Iranian scientists enjoy access to world institutions and the worldwide web of scientific information. But they do not enjoy freedom of political dissent. The nuclear deal has not changed this situation by an inch," says Eugene Chudnovsky, a physicist at the City University of New York who is co-chair of the Committee of Concerned Scientists.

The rest is here:
Jailed Iranian researcher's health worsening rapidly - Nature.com

Read More...

Stem Cell Therapies for Degenerative Disc Disease – Clinical Pain Advisor (registration)

Saturday, March 18th, 2017

Clinical Pain Advisor (registration)
Stem Cell Therapies for Degenerative Disc Disease
Clinical Pain Advisor (registration)
MSC therapy offers pain relief for patients with DDD and may slow the degenerative process of this condition. ORLANDO Mesenchymal stem cell (MSC) therapy, also known as regenerative medicine therapy, is emerging as a promising treatment for ...

View post:
Stem Cell Therapies for Degenerative Disc Disease - Clinical Pain Advisor (registration)

Read More...

Medical News Today: Vitamin C can target and kill cancer stem cells, study shows – Concord Register

Saturday, March 18th, 2017

Cancer is currently one of the top killers worldwide, and the number of cancer cases is only expected to rise. Although there are a number of therapies available, most of them are toxic and cause serious side effects. New research examines the impact of the natural vitamin C on cancer cell growth. In a recent study, vitamin C proves effective in killing cancer stem-like cells.

is the second leading cause of death and disease worldwide, accounting for almost deaths in 2015, according to the World Health Organization (WHO).

The global number of new cases of cancer are expected to grow by around 70 percent in the next 20 years.

In the United States, the National Cancer Institute (NCI) estimate that almost of U.S. men and women will have developed cancer at one point during their lives.

There are various available for cancer, but they are not always effective; most of them are toxic, and they tend to have a variety of side effects.

In some more aggressive cases, the cancer does not respond to treatment, and it is believed that cancer stem-like cells are the reason why the cancer comes back and metastasizes.

New research, in the journal Oncotarget, examines the effectiveness of three natural substances, three experimental drugs, and one clinical drug in stopping the growth of these cancer (CSCs.)

The study was conducted by researchers from the University of Salford in Manchester in the United Kingdom, and was led by Dr. Gloria Bonuccelli.

In total, the researchers measured the impact of seven substances: the clinical drug stiripentol, three experimental drugs (actinonin, FK866, and 2-DG), and three natural substances (caffeic acid phenyl ester (CAPE), silibinin, and ascorbic acid ( C).)

The research focused on the bioenergetic processes of CSCs, which enable the cells to live and multiply. The study aimed to disrupt the CSCs metabolism and ultimately prevent their growth.

Of all the substances tested, the team found that actinonin and FK866 were the most effective. However, the natural products were also found to prevent the formation of CSCs, and vitamin C was 10 times more effective than the experimental drug 2-DG.

Additionally, the study revealed that ascorbic acid works by inhibiting the process by which glucose is broken down within the cells mitochondria and turned into energy for the cells proliferation.

Dr. Michael P. Lisanti, professor of translational medicine at the University of Salford, comments on the findings:

We have been looking at how to target cancer stem cells with a range of natural substances including silibinin (milk thistle) and CAPE, a honey-bee derivative, but by far the most exciting are the results with vitamin C. Vitamin C is cheap, natural, nontoxic and readily available so to have it as a potential weapon in the fight against cancer would be a significant step.

This is further evidence that vitamin C and other nontoxic compounds may have a role to play in the fight against cancer, says the studys lead author.

Our results indicate it is a promising agent for clinical trials, and as an add-on to more conventional therapies, to prevent tumor recurrence, further disease progression, and metastasis, Bonuccelli adds.

Vitamin C has been shown to be a potent, nontoxic, anticancer agent by Nobel Prize winner Linus Pauling. However, to the authors knowledge, this is the first study providing evidence that ascorbic acid can specifically target and neutralize CSCs.

.

Written by

Read the original post:
Medical News Today: Vitamin C can target and kill cancer stem cells, study shows - Concord Register

Read More...

‘Stem cell treatment can cure blood platelet problems’ – Daijiworld.com

Friday, March 17th, 2017

New Delhi, Mar 15 (IANS): Stem cell treatment, which is effective in several health conditions, including spinal problems, can also help cure extreme blood platelet problems such as thrombocytopenia, say doctors.

The medical procedure has advantage over available treatments for blood platelet problems such as corticosteroids, blood or platelet transfusions and immunoglobulins medicines.

In a case study published in International Archives of Medicne, a 25-year-old man was treated for thrombocytopenia through stem cell therapy at a city based hospital. His laboratory examinations showed that his platelet count was 0.70 m3.

The patient underwent stem cell therapy wherein he was injected with 1 mL stem cells daily through an intravenous route.

"The patient was monitored regularly for the occurrence of any reactions during the whole therapy. Platelet count increased to 1.01m3 following the treatment and there were remarkable improvements in other symptoms," said Geeta Shroff, Stem Cell Specialist, Director, Nutech Mediworld.

Shroff has also conducted successful research on patients with spinal problems, anterior cruciate ligament tear and curing them through stem cell treatment.

According to Shroff, thrombocytopenia is defined as the reduction in blood platelet count below the normal platelet count distribution (1.5m3). It is the second most common hematological disorder after anaemia and equally affects both men and women.

The decrease in the platelet number increases the bleeding and blood loss; and when coupled with other clotting disorders can lead to serious morbidity or death.

"The proliferation and differentiating ability of stem cells has made this therapy an attractive therapeutic option. Stem cell therapy are being explored as regenerative medicine for treating various diseases due to their potential to multiply, proliferate and differentiate into any cell type.

At the injured site, stem cell produce different trophic factors and reduce the cell loss, promote host regeneration, hence, restore the function," said Shroff.

See the article here:
'Stem cell treatment can cure blood platelet problems' - Daijiworld.com

Read More...

Regulators need to protect stem cell promise – Cosmos

Friday, March 17th, 2017

Retinal cells derived from epithelial stem cells.

Silvia Riccardi/Getty Images

The report in this weeks issue of the New England Journal of Medicine (NEJM) of three people in South Florida who lost their sight after participating in what they thought was a stem cell clinical trial highlights the need for greater scrutiny by regulators to protect patients.

This is urgently needed, not just in US, but also here in Australia. While great progress has been made over the past decade, the reality is we are only just beginning to evaluate if laboratory results equate to safe and effective treatments.

Clinical trials are expected to be overseen by research ethics committees and other experts to ensure that the approach is justified. It is expected that the interests and welfare of the participants are protected, and that they are fully informed of all possible risks. It is not usually expected that patients pay to participate.

However, due to regulatory ambiguity a growing number of clinics around the world are marketing so-called stem cell treatments without first showing that they work or are safe. They are effectively bypassing the clinical trials framework or, as in this Florida case, imply that they are performing clinical research while in fact operating a business selling hope.

A quick search online finds dozens of clinics in Australia that, for a hefty fee, will treat patients suffering osteoarthritis, infertility, multiple sclerosis and hair loss with stem cells. All of these treatments are offered outside clinical trials and regulatory oversight. Evidence of benefit is weak. As they use the patients own cells, usually obtained from liposuction, the therapies are presented as safe.

For many years we and others have been concerned that patients may suffer infections or other complications, and have called on regulators to curb these exploitative practices. Even after the Coroners report into the death of an Australian woman who had an unproven stem cell treatment for dementia and died following complications associated with the procedure, little has changed.

It remains business as usual for many of these clinics.

In the absence of effective regulation, all that can be done is to continue to encourage anyone exploring stem cell therapies to do their research.

Ask lots of questions and take information back to your treating GP or specialist to discuss the implications for your condition. Raise red flags if you are asked to pay for treatment, if the same treatment is being offered for many different conditions, or where the clinic uses anecdotal stories or patient testimonies as evidence of success.

Only participate in clinical trials that have had ethics committee approval and are listed in a respected repository such as the Australian New Zealand Clinical Trial Registry. Finally, dont given up hope and maintain an active interest in the progress of stem cell research for your condition.

Despite the tragic story of the three women who are now blind, stem cell treatments to restore vision loss do hold promise. After 20 years of research, Italian scientists recently received European regulatory approval for a stem cell-based treatment for a type of blindness that results from damage to the cornea, the surface of the eye.

Other groups in the US and Japan are advancing clinical trials for macular degeneration. They first cultivate stem cells to form the retinal pigmented epithelial cells that are needed to restore a damaged retina.

Animal studies show that injecting such cells below the surface of the retina can slow the disease. We now need to responsibly assess whether this can be replicated in humans. Doing so is technically challenging, will require expert surgeons, long-term support and follow-up for the patients.

There are no guarantees that such an approach will work, although another NEJM report is promising.

Until then, regulators must step in to safeguard patient welfare and the work of those trying to support legitimate clinical translation.

Go here to read the rest:
Regulators need to protect stem cell promise - Cosmos

Read More...

These Women Went Blind After A Florida Clinic Injected Fat Cells Into Their Eyeballs – BuzzFeed News

Thursday, March 16th, 2017

Lixia Guo / BuzzFeed News

ID: 10708849

Elizabeth Noble enjoyed a full and active life, and is nobodys fool. For more than a quarter-century, she taught statistics in the School of Education at the University of Missouri-Kansas City. In retirement, she continued to work as a consultant, and travelled widely in Europe and Asia.

When Noble was diagnosed with Age-Related Macular Degeneration, which slowly blurs the sharp central vision that we rely on to read, drive, and identify faces, she wanted to do something about it. And she thought she had found an answer a research study described on ClinicalTrials.gov, a website run by the National Institutes of Health (NIH), the US governments premier biomedical research agency.

It seemed scientifically legitimate, so in June 2015 Noble went to a clinic in Sunrise, Florida, where staff sucked a small quantity of fat from around her belly button, treated it with enzymes to extract the cells it contained, and mixed those cells with a sample of Nobles blood plasma. They injected the mixture into Nobles eyeballs, charged her $5,000, and told her to avoid strenuous activity for the next three days.

US Stem Cell Clinics office in Sunrise, Florida. Google Street View

ID: 10705938

Three days later, when the 72-year-old was seen by doctors at the University of Miamis Bascom Palmer Eye Institute, strenuous activity was out of the question. Nobles eyes hurt and she was nauseous. Her retinas were bleeding and she could just make out a hand being waved in front of her face.

Nobles sight continued to deteriorate and one year later she couldnt tell the difference between night and day. Thats as bad as it gets, Thomas Albini, an ophthalmologist at the Bascom Palmer Eye Institute, told BuzzFeed News, describing the condition of the woman he identified only as Patient 1.

In the latest issue of the New England Journal of Medicine, Albini and his colleagues describe the cases of three women treated by the same stem cell company, each of whom became legally blind. The doctors dont name the women involved, but BuzzFeed News established the identities of two of them from court filings and other public documents.

This isnt the first time that people have been harmed by clinics offering unproven treatments purportedly involving stem cells. In 2010, for example, a woman with the autoimmune disease lupus died after her own bone marrow cells were injected into her kidneys at a clinic in Thailand. And in 2013, the Florida Department of Health revoked the medical license of Zannos Grekos over the death of a 69-year-old woman. He had extracted material from her bone marrow, filtered it, and then infused it into the arteries feeding her brain. The woman had a stroke, and died shortly afterwards.

But the latest tragic cautionary tale has a disturbing twist, as two of the women who were blinded contacted the company involved, now called US Stem Cells but formerly known as Bioheart, only after reading about its macular degeneration study on ClinicalTrials.gov.

The site was launched in 2000 after Congress passed a law demanding that the NIH keep a registry of clinical trials experiments with new drugs on volunteer patients so that drug companies couldnt sweep negative results under the carpet. ClinicalTrials.gov has since grown to include some 290,000 studies run in countries across the globe.

But with only minimal screening of the listings, experts who track the burgeoning and loosely regulated landscape of stem cell clinics fear that the website is being abused to claim spurious legitimacy for unproven therapies that are being sold for profit.

Its very easy to register studies on ClinicalTrials.gov and essentially use a government website as a marketing device, Leigh Turner, a bioethicist at the University of Minnesota, told BuzzFeed News.

Noble told the doctors at the Bascom Palmer Eye Institute that she thought her treatment was part of a clinical trial. Patients are not usually charged to take part in research. Yet each of the three women described in the case reports were charged $5,000, and Albini said that the consent paperwork made no mention of a study.

I think it was presented as a clinical trial and documented as a fee-for-service procedure, Albini said. In September 2015, shortly after the three women were treated, the ClinicalTrials.gov listing was amended to say the study had been withdrawn prior to enrollment.

Before that change was made, it is easy to see why Noble and Patsy Bade, who also decided to seek treatment after finding the ClinicalTrials.gov listing, might have found it convincing. It includes an long list of conditions that could exclude people from participating, and indicates that patients would be studied 6 months after their treatment, to record their field of view and the sharpness of their vision.

Neither Noble nor Bade had severe sight loss before their eyeballs were injected with material extracted from their abdominal fat. Noble still had 20/30 vision in her left eye, which is barely different from normal. Its good enough to read newspaper print, Albini said. Its very functional vision. Bade, who was 78 when she was treated and lives in Venice, Florida, struggled to read fine print and had problems driving at night. But otherwise, she could function normally.

The back of Patsy Bades left eye after the stem cell treatment. Dark patches show bleeding in the retina. Thomas Albini

ID: 10705950

These ladies who were both independent were rendered blind, their attorney, Andrew Yaffa of Grossman Roth Yaffa Cohen in Coral Gables, Florida, told BuzzFeed News. The women sued US Stem Cell, the affiliated US Stem Cell Clinic, and two medical professionals who were involved in the procedures.

The suits were settled for undisclosed sums, with a confidentiality agreement that prevents Yaffa from naming the women or the company involved. Noble and Bade also told BuzzFeed News that they were not allowed to discuss their cases.

This litigation has been resolved to the mutual satisfaction of the parties, Yaffa said.

A couple of days after her injections, Bade turned up at the Bascom Palmer Eye Institute with bleeding retinas. Again, her eyesight rapidly deteriorated. A year later, she could just detect a hand waving in front of her face with her right eye, and had 20/200 vision in her left. That is the legal threshold for blindness, and means she could read an eye chart at 20 feet only as well as a person with normal vision standing 200 feet away.

Both womens eyesight would likely still be fairly good had they not been given the injections. Macular degeneration typically proceeds pretty slowly, Albini said.

Neither Mike Toms, US Stem Cells CEO, nor Kristin Comella, the companys chief science officer, returned emails and phone calls from BuzzFeed News. Comella is described on the companys website as a world renowned expert on regenerative medicine. She is not a medical doctor, and is enrolled as a PhD student in biomedical engineering at Florida International University in Miami.

Kristin Comella, US Stem Cells chief science officer, in a promotional video. youtube.com

ID: 10708284

The company responded instead with a statement from its PR firm, Becker Public Relations, which said: Since 2001, our clinics have successfully conducted more than 7,000 stem cell procedures with less than 0.01% adverse reactions reported. We are unable to comment further on specific cases due to patient confidentiality or legal confidentiality obligations. Neither US Stem Cell nor US Stem Cell Clinic currently treats eye patients.

On its website, US Stem Cell Clinic says it offers treatments for conditions from Parkinsons disease to congestive heart failure. US Stem Cells PR company would not say how many of the 7,000 procedures the company claims to have performed involved patients with eye diseases.

While the blinding of three patients is an extreme example, experts who follow the stem cell industry worry that other people may have been harmed by clinics offering unproven treatments, without their cases coming to public attention.

What Im most worried about is that this may be the tip of the iceberg, Paul Knoepfler, a stem cell biologist at the University of California, Davis, told Buzzfeed News. Last year, he and Turner of the University of Minnesota published a survey that identified 570 clinics offering unproven stem-cell treatments across the US.

Most of these clinics argue that their treatments do not need to be regulated by the Food and Drug Administration (FDA) because they are merely injecting peoples own stem cells back into their bodies. The FDA maintains that these cells count as drugs, which it must approve for clinical use, if they are more than minimally manipulated and are not replacing cells with the same basic function.

Last September, the FDA held a two-day hearing on treatments based on human cells. The FDA is evaluating the feedback we received at the hearing, along with the written comments, as we work to finalize our guidance, agency spokesperson Andrea Fischer told BuzzFeed News by email.

Its unclear whether that will to lead to a crackdown on clinics offering unproven stem-cell treatments especially as President Donald Trumps nominee for FDA commissioner, Scott Gottlieb, in 2012 co-wrote an Op-Ed for the Wall Street Journal criticizing the agencys efforts to regulate cells as drugs.

The FDA is perennially complaining to Congress that it lacks the resources to do its day job of regulating products that fall squarely in its purview, Gottlieb and his co-author wrote. Yet in chorus, the agency is always seeking novel authority to insert itself into new areas of science where its mandate is shaky.

Whatever the FDA does next, Turner argues that the NIH should do more to screen the listings posted on ClinicalTrials.gov.

The information on ClinicalTrials.gov is provided by the study sponsor or principal investigator and posting on ClinicalTrials.gov does not necessarily reflect endorsement by the NIH, Renate Myles, an NIH spokeswoman, told BuzzFeed News by email.

Earlier today, the NIH added a similarly-worded disclaimer to the website. Myles said that the change was made because of the concerns raised by Alibinis paper.

It is time NIH representatives stopped giving boilerplate responses, Turner said. They should have addressed this problem before patients were harmed.

Go here to read the rest:
These Women Went Blind After A Florida Clinic Injected Fat Cells Into Their Eyeballs - BuzzFeed News

Read More...

Model of anorexia nervosa created using stem cells – Science Daily

Thursday, March 16th, 2017

An international research team, led by scientists at University of California San Diego School of Medicine, has created the first cellular model of anorexia nervosa (AN), reprogramming induced pluripotent stem cells (iPSCs) derived from adolescent females with the eating disorder.

Writing in the March 14th issue of Translational Psychiatry, the scientists said the resulting AN neurons -- the disease in a dish -- revealed a novel gene that appears to contribute to AN pathophysiology, buttressing the idea that AN has a strong genetic factor. The proof-of-concept approach, they said, provides a new tool to investigate the elusive and largely unknown molecular and cellular mechanisms underlying the disease.

"Anorexia is a very complicated, multifactorial neurodevelopmental disorder," said Alysson Muotri, PhD, professor in the UC San Diego School of Medicine departments of Pediatrics and Cellular and Molecular Medicine, director of the UC San Diego Stem Cell Program and a member of the Sanford Consortium for Regenerative Medicine. "It has proved to be a very difficult disease to study, let alone treat. We don't actually have good experimental models for eating disorders. In fact, there are no treatments to reverse AN symptoms."

Primarily affecting young female adolescents between ages 15 and 19, AN is characterized by distorted body image and self-imposed food restriction to the point of emaciation or death. It has the highest mortality rate among psychiatric conditions. For females between 15 and 24 years old who suffer from AN, the mortality rate associated with the illness is 12 times higher than the death rate of all other causes of death.

Though often viewed as a non-biological disorder, new research suggests 50 to 75 percent of risk for AN may be heritable; with predisposition driven primarily by genetics and not, as sometimes presumed, by vanity, poor parenting or factors related to specific groups of individuals.

But little is actually known about the molecular, cellular or genetic elements or genesis of AN. In their study, Muotri and colleagues at UC San Diego and in Brazil, Australia and Thailand, took skin cells from four females with AN and four healthy controls, generated iPSCs (stem cells with the ability to become many types of cells) from these cells and induce these iPSCs to become neurons.

(Previously, Muotri and colleagues had created stem cell-derived neuronal models of autism and Williams syndrome, a rare genetic neurological condition.)

Then they performed unbiased comprehensive whole transcriptome and pathway analyses to determine not just which genes were being expressed or activated in AN neurons, but which genes or transcripts (bits of RNA used in cellular messaging) might be associated with causing or advancing the disease process.

No predicted differences in neurotransmitter levels were observed, the researchers said, but they did note disruption in the Tachykinin receptor 1 (TACR1) gene. Tachykinins are neuropeptides or proteins expressed throughout the nervous and immune systems, where they participate in many cellular and physiological processes and have been linked to multiple diseases, including chronic inflammation, cancer, infection and affective and addictive disorders.

The scientists posit that disruption of the tachykinin system may contribute to AN before other phenotypes or observed characteristics become obvious, but said further studies employing larger patient cohorts are necessary.

"But more to the point, this work helps make that possible," said Muotri. "It's a novel technological advance in the field of eating disorders, which impacts millions of people. These findings transform our ability to study how genetic variations alter brain molecular pathways and cellular networks to change risk of AN -- and perhaps our ability to create new therapies."

Story Source:

Materials provided by University of California - San Diego. Original written by Scott LaFee. Note: Content may be edited for style and length.

See more here:
Model of anorexia nervosa created using stem cells - Science Daily

Read More...

Is Alzheimer’s treatment of injecting stem cells into the brain a breakthrough or quackery? – San Angelo Standard Times

Thursday, March 16th, 2017

Keith Sharon, The Orange County Register (TNS) 9:56 p.m. CT March 15, 2017

Jack Sage has been receiving an experimental treatment where a doctor injects stem cells into his brain to treat his Alzheimer's disease.(Photo: Paul Rodriguez, TNS)

IRVINE, Calif. More than eight years after he realized something was wrong, after, as he described it, My brain went

Whats the word? Foggy, Jack Sage finally said after several seconds of silently coaxing his synapses to fire.

More than eight years after his brain went foggy, four years after he was diagnosed with Alzheimers disease and two years since he began an innovative and extremely invasive therapy, Sage said he is being flooded by memories that seem new, or, at the very least, feel easier to retrieve. His daughter, Kate, thought Sage had suddenly begun to open up about his past because he knew his time was growing short.

He should not know who I am at this point, Kate said.

His doctor, Christopher Duma, hopes Jack Sage goes down in history as the one-man turning point in the treatment of Alzheimers disease, while others are skeptical about what Duma has done to Sages brain. Everyone agrees that Alzheimers disease is an exploding problem.

The California Alzheimers Disease Data Report from 2009 projected a 67 percent increase between 2015 and 2030 in residents in Los Angeles, Orange, Riverside and San Bernardino counties living with Alzheimers disease up to 498,137. The same report references a study, between 2000 and 2004, in which 58 percent of the deaths among people 65 and older in California were attributed to Alzheimers disease.

The Alzheimers Association reported that 610,000 Californians 65 or older had the disease in 2016, and it estimated increases to 690,000 by 2020 and 840,000 by 2025.

On a cool recent night, Sage, a handsome, fit, 82-year-old, sat next to his wife Gloria talking about his children (It is significant that Sage remembers their names James, 46, Kate, 50, and Kelly, 56), recalling when he and Gloria moved into the Newport Beach house with a view of the Pacific Ocean (1990), laughing about their first date at the Bel-Air Country Club (1979), recounting his years as a labor negotiator and executive for Del Monte, Allied Chemical and Continental Airlines (1970s and 60s) and going all the way back to the jack hammering he did in the nickel mines (mid-1950s) in Northern Ontario, Canada.

At this point in his illness, his doctor said he should be having more trouble remembering the perilous tunnels of the Sudbury nickel mine.

You drill into the granite, Sage said. You put dynamite in the rock. You dynamite it. Then you shovel out whats left.

And mining, you might say, is what is happening in Jack Sages brain.

Dr. Christopher stands in front of an MRI of Jack Sage's brain on Feb. 28, 2017 at his office in Irvine, Calif. Duma conducted phase one of clinical trials on a new treatment for Alzheimer's disease called intra-cerebro ventricular injection of autologous mesenchymal stem cells. He basically took fat cells from Jack Sage's body, spun them down to stem cells and then injected them back in to Sage's brain.(Photo: Jeff Gritchen, TNS)

Sages series of recollections, including his exploits on the golf course in Indian Wells where he has a second home and plays several days a week flashbacks representing the three main components of long-term memory: semantic (recalling the meaning of words), episodic (recalling autobiographic milestones) and procedural (recalling how to accomplish tasks) prompted a grin from Duma, the brain surgeon who, for $10,000 per treatment and without insurance coverage, cut a hole in the back of Sages head and injected a stem cell serum that had been sucked out of Sages love handles.

Is this the Alzheimers breakthrough the world has been waiting for? Or, is this unproven medical procedure what University of Minnesota bioethicist Leigh Turner calls quackery and flimflam? Is this an unsafe, money-grab it is being conducted outside the approval process of the Food and Drug Administration preying on the most vulnerable among us?

Turner has written extensively and critically about the Cell Surgical Network (CSN), for which Duma, whose home hospital is Hoag in Newport Beach, is listed as a network physician. The CSN promotes the stem cell revolution, which its literature claims, is an appropriate treatment for people suffering from a variety of inflammatory and degenerative conditions in other words, for cancer, diabetes, bad knees and hips as well as multiple uses in cosmetic surgery.

You dont just start dumping things into peoples brains, Turner said. The problem is people may spend a lot of money and find there is no benefit. He (Duma) is exposing people to serious harm. Fat cells dont belong in peoples brains.

Sage is the first patient in Phase I of a clinical study officially called Intracerebroventricular injection of autologous abdominal fat-derived, non-genetically altered stem cells. Sage was the first Alzheimers patient anywhere to have his own liposuctioned cells injected directly into his brain. He has received eight injections (about two months apart) since November 2014.

Duma quickly offers a qualifier. It is far too early to tell if what he has done to Sage will indeed change the world. He said Sage and, later, 19 other patients have not been harmed by the procedure, and that safety is the only criteria in Phase I. Whether the treatment is effective is a question for Phase II, for which Duma is hoping to attract private funding. Also, he wrote a letter to the national Alzheimers Association asking for $700,000 to continue his work. He was instructed to apply officially later this year. If he gets the grant, the fees for his patients would be waived.

Early in the process, Duma is excited by Sages results.

Sages most recent cognition scores have risen from 45 on the 100-point Memory Performance Index in March 2015 to 54 in September 2015. The volume of his hippocampus the memory center of the brain has grown from the fifth percentile before his first treatment to the 28th percentile after his fourth treatment to the 48th percentile after his eighth treatment.

My golf game is getting better, said Sage, who, heart permitting, plays several times per week. Sages brain isnt his only problem. He has a long history of heart ailments that have required the insertion of 12 stents to keep his arteries open.

You cant make a global conclusion based on one patient, but its a huge turning point, Duma said with the confidence of someone who probes brains for a living.

Duma is somewhat of a maverick in the medical world, a brain surgeon who regularly shuns a scalpel for the gamma knife, a futuristic laser for removing brain tumors. He is known outside the operating room for playing keyboards in bands that specialize in 1970s-era covers of groups such as Genesis, Yes and Emerson, Lake and Palmer. As a child, he was a classmate of John F. Kennedy Jr. at The Browning School in New York City. We called him John John, Duma said.

Duma realizes he will face opposition to his stem cell/brain injection therapy. But, as in all breakthroughs, someone has to be first.

I could have harmed people, he said. I took an enormous leap.

Alzheimers patients dont get better.

They get diagnosed, lose their dignity and die.

The speed at which death occurs is the only variable.

In the depressing world of Alzheimers treatment, Sage and Duma represent equal parts hope and skepticism. The Orange County Register contacted universities and research centers across the country, including Stanford, Harvard, Duke, Florida International, UC Davis, and some of the interview requests were denied while other calls were not returned. Very few medical experts want to talk about the combination of stem cells and Alzheimers disease, apparently because they know so little about it.

An Alzheimers patient improving because of therapy? Im hopeful its true. Im hopeful its true for all patients, said Joshua Grill, the co-director of the Memory Impairments Neurological Disorders (MIND) institute at UC Irvine. We are in dire need.

Jack Sage and his wife Gloria react in January to the positive results of Jack's latest MRI from Dr. Christopher Duma, left, at their home in Corona del Mar, Calif. More than eight years after his brain went foggy, four years after he was diagnosed with Alzheimer's disease and two years since he began an innovative and extremely invasive therapy, Sage said he is being flooded by memories that seem new, or, at the very least, feel easier to retrieve.(Photo: Paul Rodriguez, TNS)

But, Grill continued, One study does not a revolution make. Ive never read anything about this (Dumas work), and I dont know what science is behind it.

Dean Hartley, Director of Science Initiatives at the Alzheimers Association, knew about Dumas work.

This is new territory, Hartley said. But with one patient, No, you cannot say this is a game-changer.

Hartley said many studies fail at the Phase II level, where more and more people are exposed to the therapy.

Still, Hartley said Dumas work is encouraging.

We want to see things like this happen, Hartley said.

Its not as if Duma is conducting his research in secret. He spoke about his study in public forums twice last year Sept. 28 at the Congress of Neurological Surgeons in San Diego, and Oct. 1 at the International Society for Cellular Therapy in Memphis.

Duma said he is nearly finished writing a paper about his work that he hopes will be published in a peer-reviewed journal.

In 1993, Christopher Duma was working at Good Samaritan Hospital in Los Angeles when he and his colleagues began injecting stem cells into the brains of patients with Parkinsons disease. They were making some progress, he said, but politics intervened. Some of the stem cells they were using came from aborted fetuses. Pressure from anti-abortion groups shut that program down.

Fifteen years later, Duma was assisting plastic surgeon Michael Elam on a face-lift on a Parkinsons patient when Elam said, We need to talk about stem cells.

Elam introduced Duma to Drs. Mark Berman and Elliot Lander, the founders of the Cell Surgical Network.

Berman and Lander had been separating stem cells from fat by using a centrifuge (which they own the patent for) and injecting them into knees and hips and other places where injuries had occurred. Their work had passed an Institutional Review Board after 1,524 patients were treated with no adverse effects, Berman said.

If you want to repair an injury, Berman said, the best tissue is the stem cell.

In 2013, Duma suggested a new target for stem cell therapy: the brain.

Duma, with Berman, Lander and Elam as co-authors, tried to begin a study of brain/stem cell injections. But their first attempt at Institutional Review Board approval was denied because they hadnt done animal testing. So they got Dr. Oleg Kopyov at Cal State Northridge to conduct tests on rats.

With the help of Kopyovs work, Duma got Institutional Review Board approval. They chose not to take the usual next step FDA approval.

The Institutional Review Board was expecting us to go through the FDA, Lander said. But there are hundreds of obstructions. The FDA approval process usually takes between eight and 12 years, according to the online journal Medscape.com.

Duma said stem cells present a quandary for the FDA because stem cells are not a drug, and theyre not food. Clinics that take stem cells out of the body and put them back in without additives argue that they are exempt from FDA mandates.

We have been harvesting fat from abdomens and putting them in the brain during brain surgeries since the 1920s, Duma said. We do it nearly on every case for pituitary tumors, acoustic and skull base tumors and for conditions of spinal fluid leakage since the 1920s. If the FDA ruled that harvested autologous fat cannot be used in the brain, then it would change nearly a century of neurosurgical standard of care.

Someday, Duma said he hopes the FDA will recognize his work.

The work cant wait, he said.

Jack Sage and his wife Gloria at their home in Corona del Mar in January.(Photo: Paul Rodriguez, TNS)

In August 2013, Jack Sage staggered into the office of Dr. William Shankle in Newport Beach.

Shankle, a renowned expert in cognitive disease he is the author of the Memory Performance Index that is used around the world diagnosed Sage with two problems: Alzheimers disease and hydrocephalus (fluid on the brain). Sage needed a shunt in his brain to drain the fluid and relieve the pressure.

So Shankle walked him down the hall (their offices are yards apart on the same floor in the same building) and introduced Sage to Christopher Duma, medical director of Hoag Hospitals Brain Tumor Program, and the surgeon who would put in the shunt.

Duma remembers that first meeting. Sage was in straight-line cognitive decline, Duma said.

Shankle would not grant an interview about Duma or his treatment. Shankle said he is wary of hocus pocus about Alzheimers disease without saying that Duma has done anything wrong. More than a decade ago, Shankle tried a surgical stem cell therapy on patients. He removed patients stem-cell-rich omentum, a fatty sheath covering the abdomen, cut open their skulls and stretched the omentum directly on their brain. Four of the six patients he studied had serious complications from the surgery.

The patients improved in cognitive tests, but the surgery was too much for them.

The method of delivering the treatment was radical (surgical transposition of the greater omentum to the surface of the brain while keeping the blood supply intact), Shankle wrote in an email. After showing that it really works, my goal was to never do the surgery again but find a different way of delivering these critical factors less invasively.

Sage was the patient Duma had been waiting for.

Jack was a man who was doomed, Duma said. He looked like classic Alzheimers. He had no ability to follow a train of thought. He was asking and re-asking the same questions. People like Jack are there, but theyre not there.

Sage was perfect for Duma for other reasons. He has always been a fitness nut cycling, tennis, golf, skiing and 10K runs were all part of his lifestyle. Kate Sage said he has been ordering salmon and spinach for dinner at restaurants for years.

Jack is the experimental model, Duma said. He is the brave one.

During two years of treatments, Sage has either maintained or slightly improved his cognitive health. He had a major heart attack in 2016, making his brain less of a cause for concern than his heart.

Kate said she doesnt know if Dumas treatment is working.

Its hard for me to say this is miraculous, Kate said.

She said she doesnt worry about his brain as much anymore.

Hes going to drop dead with some kind of a heart thing, she said. Hes not going to lose his memory.

Jack Sage passed his written test recently to renew his driver's license.(Photo: Paul Rodriguez, TNS)

The tragedy of Alzheimers disease is that it not only steals the history that makes us who we are. It takes our skills, our beliefs, our independence, our ability to love.

So far, Jack Sage is still Jack Sage. Obviously, he doesnt know if he would be the same without Dumas treatments.

I can tell Im getting better and better, Sage said. Is that pure optimism? The Placebo Effect?

In January, Jack Sages drivers license came up for renewal. He said hes able to remember driving directions without problem. He still navigates the route from his home in Newport Beach to his other home in Indian Wells. But, he was required to pass the written test, and Sage feared he wouldnt be able to remember the complex rules of the road.

I was worried, he said.

But he passed, and his license was extended five years.

His improved memory, he said, sometimes catches him by surprise.

These memories come up when I dont even think about it, Sage said.

Sometimes, the memories take Sage places he doesnt want to go.

When he worked in the nickel mines in the 1950s, he and his first wife had a son.

His name was Mark, Sage said, speaking slowly as if the memory was bubbling up from depths he didnt want to consider. We rented a house with a playroom. My wife went shopping, and I was upstairs

I was working on my school work for McMaster University

Mark fell

we had a drainage basin inside the house

when I got to him, he was gone

Sage stopped talking as if flooded by new emotions over the death of his son.

We were distraught, he said. It was tough times for years.

In the murky world of Alzheimers therapy, Jack Sage is still mining.

Read or Share this story: http://www.gosanangelo.com/story/life/wellness/2017/03/15/alzheimers-treatment-injecting-stem-cells-into-brain-breakthrough-quackery/99240794/

Read the original here:
Is Alzheimer's treatment of injecting stem cells into the brain a breakthrough or quackery? - San Angelo Standard Times

Read More...

Researchers create model of anorexia nervosa using stem cells – Medical Xpress

Tuesday, March 14th, 2017

March 14, 2017

An international research team, led by scientists at University of California San Diego School of Medicine, has created the first cellular model of anorexia nervosa (AN), reprogramming induced pluripotent stem cells (iPSCs) derived from adolescent females with the eating disorder.

Writing in the March 14th issue of Translational Psychiatry, the scientists said the resulting AN neuronsthe disease in a dishrevealed a novel gene that appears to contribute to AN pathophysiology, buttressing the idea that AN has a strong genetic factor. The proof-of-concept approach, they said, provides a new tool to investigate the elusive and largely unknown molecular and cellular mechanisms underlying the disease.

"Anorexia is a very complicated, multifactorial neurodevelopmental disorder," said Alysson Muotri, PhD, professor in the UC San Diego School of Medicine departments of Pediatrics and Cellular and Molecular Medicine, director of the UC San Diego Stem Cell Program and a member of the Sanford Consortium for Regenerative Medicine. "It has proved to be a very difficult disease to study, let alone treat. We don't actually have good experimental models for eating disorders. In fact, there are no treatments to reverse AN symptoms."

Primarily affecting young female adolescents between ages 15 and 19, AN is characterized by distorted body image and self-imposed food restriction to the point of emaciation or death. It has the highest mortality rate among psychiatric conditions. For females between 15 and 24 years old who suffer from AN, the mortality rate associated with the illness is 12 times higher than the death rate of all other causes of death.

Though often viewed as a non-biological disorder, new research suggests 50 to 75 percent of risk for AN may be heritable; with predisposition driven primarily by genetics and not, as sometimes presumed, by vanity, poor parenting or factors related to specific groups of individuals.

But little is actually known about the molecular, cellular or genetic elements or genesis of AN. In their study, Muotri and colleagues at UC San Diego and in Brazil, Australia and Thailand, took skin cells from four females with AN and four healthy controls, generated iPSCs (stem cells with the ability to become many types of cells) from these cells and induce these iPSCs to become neurons.

(Previously, Muotri and colleagues had created stem cell-derived neuronal models of autism and Williams syndrome, a rare genetic neurological condition.)

Then they performed unbiased comprehensive whole transcriptome and pathway analyses to determine not just which genes were being expressed or activated in AN neurons, but which genes or transcripts (bits of RNA used in cellular messaging) might be associated with causing or advancing the disease process.

No predicted differences in neurotransmitter levels were observed, the researchers said, but they did note disruption in the Tachykinin receptor 1 (TACR1) gene. Tachykinins are neuropeptides or proteins expressed throughout the nervous and immune systems, where they participate in many cellular and physiological processes and have been linked to multiple diseases, including chronic inflammation, cancer, infection and affective and addictive disorders.

The scientists posit that disruption of the tachykinin system may contribute to AN before other phenotypes or observed characteristics become obvious, but said further studies employing larger patient cohorts are necessary.

"But more to the point, this work helps make that possible," said Muotri. "It's a novel technological advance in the field of eating disorders, which impacts millions of people. These findings transform our ability to study how genetic variations alter brain molecular pathways and cellular networks to change risk of ANand perhaps our ability to create new therapies."

Explore further: Stem cell-derived 'mini-brains' reveal potential drug treatment for rare disorder

More information: P D Negraes et al, Modeling anorexia nervosa: transcriptional insights from human iPSC-derived neurons, Translational Psychiatry (2017). DOI: 10.1038/tp.2017.37

Using "mini-brains" built with induced pluripotent stem cells derived from patients with a rare, but devastating, neurological disorder, researchers at University of California, San Diego School of Medicine say they have ...

Researchers at University of California, San Diego School of Medicine and Rady Children's Hospital-San Diego have created the first stem cell-derived in vitro cellular model of a rare, but devastating, neurodegenerative condition ...

With the help of mouse models, induced pluripotent stem cells (iPSCs) and the "tooth fairy," researchers at the University of California, San Diego School of Medicine have implicated a new gene in idiopathic or non-syndromic ...

In a study spanning molecular genetics, stem cells and the sciences of both brain and behavior, researchers at University of California San Diego, with colleagues at the Salk Institute of Biological Studies and elsewhere, ...

An international team of scientists led by researchers at the University of California, San Diego School of Medicine have used induced pluripotent stem cells (iPSCs) derived from patients with amyotrophic lateral sclerosis ...

Researchers at Karolinska Institutet collaborating in the large-scale Karolinska Schizophrenia Project are taking an integrative approach to unravel the disease mechanisms of schizophrenia. In the very first results now presented ...

To combat the effects of a poor diet, probiotics may be just the thing. However, surprising new research from UNSW suggests probiotics are much less effective when taken alongside a balanced diet, and could even impair certain ...

In a small-scale study of women with previously diagnosed mood disorders, Johns Hopkins researchers report that lower levels of the hormone allopregnanolone in the second trimester of pregnancy were associated with an increased ...

An international research team, led by scientists at University of California San Diego School of Medicine, has created the first cellular model of anorexia nervosa (AN), reprogramming induced pluripotent stem cells (iPSCs) ...

A dietary supplement kit, created to counter mood-altering brain changes linked to depression, virtually eliminated the "baby blues" among women in a new study at Toronto's Centre for Addiction and Mental Health (CAMH).

A study has shown thatcontrary to popular beliefolder people make riskier decisions than younger adults. Older people's generally more positive emotions make them more optimistic when gauging risks. In addition, older ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See more here:
Researchers create model of anorexia nervosa using stem cells - Medical Xpress

Read More...

‘Stem cell treatment can cure blood platelet problems’ – Business Standard

Tuesday, March 14th, 2017

IANS | New Delhi March 14, 2017 Last Updated at 22:14 IST

Stem cell treatment, which is effective in several health conditions, including spinal problems, can also help cure extreme blood platelet problems such as thrombocytopenia, say doctors.

The medical procedure has advantage over available treatments for blood platelet problems such as corticosteroids, blood or platelet transfusions and immunoglobulins medicines.

In a case study published in International Archives of Medicne, a 25-year-old man was treated for thrombocytopenia through stem cell therapy at a city based hospital. His laboratory examinations showed that his platelet count was 0.70 m3.

The patient underwent stem cell therapy wherein he was injected with 1 mL stem cells daily through an intravenous route.

"The patient was monitored regularly for the occurrence of any reactions during the whole therapy. Platelet count increased to 1.01m3 following the treatment and there were remarkable improvements in other symptoms," said Geeta Shroff, Stem Cell Specialist, Director, Nutech Mediworld.

Shroff has also conducted successful research on patients with spinal problems, anterior cruciate ligament tear and curing them through stem cell treatment.

According to Shroff, thrombocytopenia is defined as the reduction in blood platelet count below the normal platelet count distribution (1.5m3). It is the second most common hematological disorder after anaemia and equally affects both men and women.

The decrease in the platelet number increases the bleeding and blood loss; and when coupled with other clotting disorders can lead to serious morbidity or death.

"The proliferation and differentiating ability of stem cells has made this therapy an attractive therapeutic option. Stem cell therapy are being explored as regenerative medicine for treating various diseases due to their potential to multiply, proliferate and differentiate into any cell type.

At the injured site, stem cell produce different trophic factors and reduce the cell loss, promote host regeneration, hence, restore the function," said Shroff.

--IANS

rup/lok/dg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Stem cell treatment, which is effective in several health conditions, including spinal problems, can also help cure extreme blood platelet problems such as thrombocytopenia, say doctors.

The medical procedure has advantage over available treatments for blood platelet problems such as corticosteroids, blood or platelet transfusions and immunoglobulins medicines.

In a case study published in International Archives of Medicne, a 25-year-old man was treated for thrombocytopenia through stem cell therapy at a city based hospital. His laboratory examinations showed that his platelet count was 0.70 m3.

The patient underwent stem cell therapy wherein he was injected with 1 mL stem cells daily through an intravenous route.

"The patient was monitored regularly for the occurrence of any reactions during the whole therapy. Platelet count increased to 1.01m3 following the treatment and there were remarkable improvements in other symptoms," said Geeta Shroff, Stem Cell Specialist, Director, Nutech Mediworld.

Shroff has also conducted successful research on patients with spinal problems, anterior cruciate ligament tear and curing them through stem cell treatment.

According to Shroff, thrombocytopenia is defined as the reduction in blood platelet count below the normal platelet count distribution (1.5m3). It is the second most common hematological disorder after anaemia and equally affects both men and women.

The decrease in the platelet number increases the bleeding and blood loss; and when coupled with other clotting disorders can lead to serious morbidity or death.

"The proliferation and differentiating ability of stem cells has made this therapy an attractive therapeutic option. Stem cell therapy are being explored as regenerative medicine for treating various diseases due to their potential to multiply, proliferate and differentiate into any cell type.

At the injured site, stem cell produce different trophic factors and reduce the cell loss, promote host regeneration, hence, restore the function," said Shroff.

--IANS

rup/lok/dg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

IANS

http://bsmedia.business-standard.com/_media/bs/wap/images/bs_logo_amp.png 177 22

See the original post:
'Stem cell treatment can cure blood platelet problems' - Business Standard

Read More...

Belgium’s Tigenix says heart attack stem cell trial successful – KFGO

Tuesday, March 14th, 2017

Monday, March 13, 2017 3 a.m. CDT

BRUSSELS (Reuters) - Belgian biotech group Tigenix said on Monday its medical trial with a novel treatment for patients at risk of heart failure after a coronary attack was successful.

The group said patients treated in its PhaseI/II trial of donor-derived expanded cardiac stem cells (AlloCSC) showed no side-effects and all of them continued to live after 30 days, six months and a year.

Tigenix added that in one subgroup of trial patients associated with a poor long-term outlook, there was a larger reduction in the size of infarction, tissue death due to inadequate blood supply.

"This is the first trial in which it has been demonstrated that allogeneic cardiac stem cells can be transplanted safely through the coronary tree," one of the doctors in the trial said.

The group said it would now analyze the data from the trial and decide on how to proceed with its research.

(Reporting by Robert-Jan Bartunek; editing by Philip Blenkinsop)

Read the rest here:
Belgium's Tigenix says heart attack stem cell trial successful - KFGO

Read More...

Vitamin C can target and kill cancer stem cells, study shows … – Medical News Today

Monday, March 13th, 2017

Cancer is currently one of the top killers worldwide, and the number of cancer cases is only expected to rise. Although there are a number of therapies available, most of them are toxic and cause serious side effects. New research examines the impact of the natural vitamin C on cancer cell growth.

Cancer is the second leading cause of death and disease worldwide, accounting for almost 9 million deaths in 2015, according to the World Health Organization (WHO).

The global number of new cases of cancer are expected to grow by around 70 percent in the next 20 years.

In the United States, the National Cancer Institute (NCI) estimate that almost 40 percent of U.S. men and women will have developed cancer at one point during their lives.

There are various treatment options available for cancer, but they are not always effective; most of them are toxic, and they tend to have a variety of side effects.

In some more aggressive cases, the cancer does not respond to treatment, and it is believed that cancer stem-like cells are the reason why the cancer comes back and metastasizes.

New research, published in the journal Oncotarget, examines the effectiveness of three natural substances, three experimental drugs, and one clinical drug in stopping the growth of these cancer stem cells (CSCs.)

The study was conducted by researchers from the University of Salford in Manchester in the United Kingdom, and was led by Dr. Gloria Bonuccelli.

In total, the researchers measured the impact of seven substances: the clinical drug stiripentol, three experimental drugs (actinonin, FK866, and 2-DG), and three natural substances (caffeic acid phenyl ester (CAPE), silibinin, and ascorbic acid (vitamin C).)

The research focused on the bioenergetic processes of CSCs, which enable the cells to live and multiply. The study aimed to disrupt the CSCs' metabolism and ultimately prevent their growth.

Of all the substances tested, the team found that actinonin and FK866 were the most effective. However, the natural products were also found to prevent the formation of CSCs, and vitamin C was 10 times more effective than the experimental drug 2-DG.

Additionally, the study revealed that ascorbic acid works by inhibiting glycolysis - the process by which glucose is broken down within the cell's mitochondria and turned into energy for the cell's proliferation.

Dr. Michael P. Lisanti, professor of translational medicine at the University of Salford, comments on the findings:

"We have been looking at how to target cancer stem cells with a range of natural substances including silibinin (milk thistle) and CAPE, a honey-bee derivative, but by far the most exciting are the results with vitamin C. Vitamin C is cheap, natural, nontoxic and readily available so to have it as a potential weapon in the fight against cancer would be a significant step."

"This is further evidence that vitamin C and other nontoxic compounds may have a role to play in the fight against cancer," says the study's lead author.

"Our results indicate it is a promising agent for clinical trials, and as an add-on to more conventional therapies, to prevent tumor recurrence, further disease progression, and metastasis," Bonuccelli adds.

Vitamin C has been shown to be a potent, nontoxic, anticancer agent by Nobel Prize winner Linus Pauling. However, to the authors' knowledge, this is the first study providing evidence that ascorbic acid can specifically target and neutralize CSCs.

Learn how 300 oranges' worth of vitamin C can impair cancer cells.

See the original post here:
Vitamin C can target and kill cancer stem cells, study shows ... - Medical News Today

Read More...

Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed? – Xconomy

Monday, March 13th, 2017

Xconomy National

Its a struggle that comic-book fans know well. Ordinary people, bestowed with super powers from a spider bite or gamma rays, struggle to harness their own abilities.

T cells, key soldiers of the immune system, are wrestling with new-found super powers, too. Certain T cells hunt down invasive viruses, bacteria, and the bodys own bad seedsthe early signs of cancer. But cancer has ways of evading the immune system, so researchers are engineering T cells to give them extra cancer-fighting talents. These so-called CAR-T treatments, administered experimentally in clinical trials, have helped dozens of patients with otherwise untreatable blood cancers.

Now the fields first-ever regulatory approval is looking like a strong possibility, making this a watershed year for CAR-T therapy. But the supercharged T cells remain an enigma. Experts are wrestling with the super-hero problem that threatens to limit their usefulness: How can the cells be engineered to kill cancer without running amok?

Its more important than anything else to keep learning how CAR-T cells work and how they potentially carry risk, says Amir Fathi, an assistant professor of medicine at Harvard Medical School. As director of the leukemia program at Massachusetts General Hospital in Boston, Fathi treats patients with experimental CAR-T therapies.

(CAR-T stands for chimeric antigen receptor T cells, which describes the modification that picks up the signals of tumor cellssensitive T cell spyware, if you will.)

With Kite Pharma (NASDAQ: KITE) of Santa Monica, CA, nearly ready to ask the FDA to review its CAR-T axicabtagene ciloleucel as a treatment for adults with non-Hodgkin lymphoma (NHL), the fields first-ever approval could be months away. International drug giant Novartis (NYSE: NOV) might not be far behind, with a CAR-T for pediatric patients with acute lymphoblastic leukemia (ALL).

For now, the Kite and Novartis products are meant for narrow groups of patients who have failed to improve with other therapies, including chemotherapy and bone-marrow transplant. Their doctors are thrilled to have the first generation CAR-Ts. The patients whom these trials are targeting, theyre typically highly refractory, they have no options left, says Krishna Komanduri, director of the Sylvester Cancer Center Adult Stem Cell Transplant Program at the University of Miami.

But is a last-ditch lifeline for patients with severe cases of two blood cancers the ceiling for CAR-T? Doctors, patients, and investors who have poured billions of dollars into the field have much higher hopes that the living cells will stand alone as long-term treatments, even cures, not just improvements upon current standards or temporary bridges to get patients healthy enough for bone-marrow transplantswhich are fraught with risks, too.

The risk of dying from transplants has come down under 20 percent in recent years, which is still higher than the overall death risk from CAR-T. But transplants are proven to cure cancer; CAR-T therapy has a long way to go. I think we need to see no evidence of disease [in patients] for several years, ideally three to five, before even comparing it to transplant, says Vinay Prasad, a blood cancer specialist at Oregon Health & Science University in Portland, and a critic of what he sees as a rush to useand pay forexpensive new medicines and procedures.

Ambitions also include eventual treatment of more common solid tumorsbreast, colon, and lung, for example. But the obstacles in realizing those ambitionsunderstanding CAR-Ts potentially deadly side effects, training a wide range of medical staff, and convincing healthcare insurers that the treatments are worth paying forwill not be easy to surmount. As Komanduri notes, bone marrow transplants from donors have been known for decades to cure lymphoma, but inadequate Medicare coverage has held the field back. The endgame should not be proving that a technology works in the clinical trial setting and securing FDA approval, says Komanduri, but ensuring we have a framework that maximizes access to curative treatments in a sustainable way.

SIDE EFFECTS, DEATHS, AND RELAPSES

As noted in Xconomys searchable CAR-T clinical results database, many programs have had stunning early results. More than 80 percent of leukemia patients, for example, have shown no signs of cancer a few weeks after treatment. Relapse rates climb after a few months in most studies. Lymphoma patients have had lower rates of remission, but in the Kite Pharma program that could be up for approval this year, the rates have stayed stable for six monthsa big deal in the CAR-T world.

Significant side effects are likely to limit CAR-T therapy to major treatment centers that can handle their unpredictability and sudden severity. Doctors working on CAR-T studies say theyre getting a handle on one common side effect, called cytokine release syndrome, with steroids and other drugs. But CAR-T treatments are also causing Next Page

Alex Lash is Xconomy's National Biotech Editor. He is based in San Francisco.

Go here to see the original:
Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed? - Xconomy

Read More...

Belgium’s Tigenix says heart attack stem cell trial successful – Reuters

Monday, March 13th, 2017

BRUSSELS Belgian biotech group Tigenix said on Monday its medical trial with a novel treatment for patients at risk of heart failure after a coronary attack was successful.

The group said patients treated in its PhaseI/II trial of donor-derived expanded cardiac stem cells (AlloCSC) showed no side-effects and all of them continued to live after 30 days, six months and a year.

Tigenix added that in one subgroup of trial patients associated with a poor long-term outlook, there was a larger reduction in the size of infarction, tissue death due to inadequate blood supply.

"This is the first trial in which it has been demonstrated that allogeneic cardiac stem cells can be transplanted safely through the coronary tree," one of the doctors in the trial said.

The group said it would now analyze the data from the trial and decide on how to proceed with its research.

(Reporting by Robert-Jan Bartunek; editing by Philip Blenkinsop)

NEW YORK The Trump administration told states on Monday that it was opening the door for them to make changes to their health insurance programs by using a section of the 2010 Affordable Care Act that gives them the flexibility to do so.

Local transmission of the Zika virus in Florida may have occurred as early as June 15 of last year and likely infected people who lived not only in Miami-Dade County, but in two nearby counties, U.S. health officials said on Monday.

(Reuters Health) - - U.S. patients are more likely to experience gaps in coordination among healthcare providers than their counterparts in other high-income nations, a new study suggests.

See the rest here:
Belgium's Tigenix says heart attack stem cell trial successful - Reuters

Read More...

Plaque unveiled for man behind HelpSaveMatthew.com who died of … – Montreal Gazette

Monday, March 13th, 2017

Montreal Gazette
Plaque unveiled for man behind HelpSaveMatthew.com who died of ...
Montreal Gazette
Ceremony was held in Laval on Sunday to unveil plaque for cancer patient and fundraiser Matthew Schreindorfer, who died in February.

and more »

Excerpt from:
Plaque unveiled for man behind HelpSaveMatthew.com who died of ... - Montreal Gazette

Read More...

‘The Persistence’ (PS4) Announced – Screens & Trailer – WorthPlaying.com

Saturday, March 11th, 2017

The Persistence is set onboard a research vessel sent to study a collapsing star, but when an experiment triggers a catastrophic failure, the ships computer attempts to save the day by reconstructing the deceased crewmembers. Unfortunately, it also introduces hideous errors in the process, transforming them into gibbering mutants.

Playing as a crewmember awoken from cryosleep, youll navigate the doomed ship, try to get the engines back online, and escape the ravenous clutches of the nearby black hole.

The ship itself is procedurally generated, so each time you die, youll awaken as a new character facing a new ship layout, different threats, and new opportunities. And die you will death is an integral part of the gameplay loop.

As you play, youll collect stem cells youll use to enhance your character after death. Benefits like increased speed, health, and stealth that will help you stay alive long enough to complete the game.

As for weapons, your trusty sidearm is the Stem Cell Harvester, which syphons precious cells from enemies, with fatal results. The Gravity Bomb drops a miniature black hole to devour nearby mutants, while a Rage Serum injector grants you temporary super-strength for hand-to-hand pummeling. There are more conventional firearms, too, including a pistol that fires dark-energy-infused rounds.

There will also be a tablet/smartphone companion app where nearby players can log in to the ships computer to view the level layout and identify upcoming threats or items, and either decide to help or hinder you.

See the article here:
'The Persistence' (PS4) Announced - Screens & Trailer - WorthPlaying.com

Read More...

African strain of Zika kills placenta cells in days – Futurity: Research News

Friday, March 10th, 2017

Infection of pregnant women by the Asian strain of Zika virus has been linked to brain abnormalities such as microcephaly in their infants. Its not clear, however,at what stage of pregnancy the human fetus is most susceptible to the disease.

Anew study shows the human fetus may be most vulnerable to Zika infection very early in pregnancy. In addition, the lesser-known African strain of Zika might possibly cause nearly immediate death of the placenta. Researchers say the findings could lead to the development of stronger defenses in the global fight against Zika.

Although the placenta is an effective barrier to the transmission of certain diseases and pathogens, the Asian strain, which has been linked to microcephaly in humans, is generally thought to cross through the placenta, says R. Michael Roberts, professor of animal science and of biochemistry at the University of Missouri.

Spread mostly by infected mosquitos, incidences of the virus can be found throughout US states and territories where more than 3,100 cases in pregnant women, mainly travelers from countries where the disease is widespread, have been reported to the Centers for Disease Control and Prevention.

For the new study, published in the Proceedings of the National Academy of Sciences, researchers created placental cells from an approved line of pluripotent stem cells that were similar to early stage placentas. These placental cells were then infected with an Asian and African strain of Zika virus to determine how the placental cells were affected by the viruses.

Zika enters its target cells in a complex, multistep process, says Megan A. Sheridan, a graduate student in Roberts lab. We found that the Asian strain of the virus infected and replicated in the cells; however, it didnt kill the cells as readily.

Our research suggests that the Asian strain infects the placenta in the early stages of pregnancy and essentially lies in wait where it is then transmitted to the fetus causing neurological disorders in infants such as microcephaly.

The team noticed substantially different results when placental cells were introduced to the African strain of the Zika virus. When exposed, placental cells were killed within days, indicating that African strain of Zika could possibly cause miscarriages in infected mothers.

The results from our testing of the African strain were unexpected, Roberts says. The cells were killed within 40-48 hours meaning that African Zika, while less prevalent, could be much more deadly during early pregnancy.

The findings suggest that the developing fetus could be most vulnerable to infection by Zika virus and other pathogens during a relatively narrow window within the first trimester of pregnancy.

The National Institutes of Health and Fundao de Amparo a Pesquisa do Estado de So Paulo funded the work. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Source: University of Missouri

Read more:
African strain of Zika kills placenta cells in days - Futurity: Research News

Read More...

How ‘Cannibalism’ by Breast Cancer Cells Promotes Dormancy – Observer

Friday, March 10th, 2017

Observer
How 'Cannibalism' by Breast Cancer Cells Promotes Dormancy
Observer
Cancer cells, in red, cannibalize a type of stem cell, shown in green. The red cells with small specks of green are breast cancer cells that have eaten the stem cell. Author provided. Breast cancer death rates overall have steadily declined since ...

and more »

See the original post:
How 'Cannibalism' by Breast Cancer Cells Promotes Dormancy - Observer

Read More...

How ‘cannibalism’ by breast cancer cells promotes dormancy: A possible clue into cancer recurrence – Medical Xpress

Thursday, March 9th, 2017

March 8, 2017 by Thomas Bartosh, The Conversation Cancer cells, in red, cannibalize a type of stem cell, shown in green. The red cells with small specks of green are breast cancer cells that have eaten the stem cell.

Breast cancer death rates overall have steadily declined since 1989, leading to an increased number of survivors. But while breast cancer survivors are grateful their bodies show no trace of the disease, they still face anxiety. Breast cancer can and does return, sometimes with a vengeance, even after being in remission for several years.

By studying the "cannabilistic" tendency of cancer cells, my research team has made some progress in finding out why.

The chances of recurrence and disease outcome vary with cancer subtype. About one-third of patients diagnosed with triple negative breast cancer, the most aggressive subtype, may experience a recurrence in another part of the body. This is called distant recurrence.

It has been difficult, if not impossible, to predict if and when the same cancer will recur and to stop it. Recurrent disease may arise from just a single cancer cell that survived the initial treatment and became dormant. The dormancy allowed it to hide somewhere in the body, not growing or causing harm for an unpredictable amount of time.

Determining what puts these dormant cells to "sleep" and what provokes them to "wake up" and begin multiplying uncontrollably could lead to important new treatments to prevent a demoralizing secondary cancer diagnosis.

Recently, my research team and I uncovered several clues that might explain what triggers these breast cancer cells to go dormant and then "reawaken." We showed that cell cannibalism is linked to dormancy.

How do bone stem cells affect breast cancer?

Breast cancer can recur in the breast or in other organs, such as the lungs and bone. Where breast cancer decides to grow depends largely on the microenvironment. This refers to the cells that surround it, including immune cells, cells comprising blood vessels, fibroblasts and the select proteins they produce, among other factors.

Over a century ago, a surgeon named Stephen Paget famously compared the organ-specific prevalence of cancer metastasis to seeds and soil. Because breast cancer often relapses in bones, in this metaphor, which still holds forth today, the bone marrow provides a favorable microenvironment (the "soil") for dormant breast cancer cells (the "seeds") to thrive.

Thus, a substantial amount of recent work has involved trying to determine the role in cancer dormancy of a special type of cell, called mesenchymal stem cells (MSCs). These are found in bone marrow.

MSCs in bone marrow are highly versatile. They are able to form bone, cartilage and fibrous tissue, as well as cells that support the immune system and formation of blood. They are also known to travel to sites of tissue injury and inflammation, where they aid in healing.

Breast cancer cells readily interact with MSCs if they meet in the bone marrow. They also readily interact if the breast cancer cells recruit them to the site of the primary tumor.

My research team and I recently focused on potential outcomes of these cellular interactions. We found an odd thing happens, which may provide insight into how these breast cancer cells hide for a long time.

In the laboratory setting, we produced breast tumor models containing MSCs. We also re-created the hostile conditions that naturally challenge developing tumors in patients, such as localized nutrient deficits caused by rapid growth of cancer cells and overcrowding.

We discovered that cancer cells under this duress become dormant after eating, or "cannibalizing," the stem cells.

Our analysis provided compelling data demonstrating that the cannibalistic breast cancer cells did not form tumors as rapidly as other cancer cells, and sometimes not at all. At the same time, they became highly resistant to chemotherapy and stresses imposed by nutrient deprivation.

Dormant cells are widely linked to recurrence. We hypothesize that cannibalism thus is linked to recurrence.

What is cellular cannibalism, and why is it important in cancer?

Cellular cannibalism, in general, describes a distinct phenomenon in which one cell engulfs and eliminates neighboring, intact cells.

The percentage of cancer cells that show cannibalistic activity is relatively low, but it does appear to increase in more aggressive tumors.

There are several reasons breast cancer cells would want to eat other cells, including other cancer cells. It provides them with a way to feed when nutrients are in short supply. It also provides them a way to eliminate the very immune cells that naturally stop cancer growth. Cell cannibalism might also allow cancer cells to inherit new genetic information and, therefore, new and advantageous traits.

Notably, in our study, cannibalistic breast cancer cells that ate the stem cells and entered dormancy began to produce an array of specific proteins. Many of these proteins are also secreted by normal cells that have permanently stopped dividing, or senescent cells, and have been collectively termed the senescence-associated secretory phenotype (or SASP). Although cellular senescence is a part of aging, we are now realizing that it is also important for a variety of normal bodily processes, development of embryos and injury repair in adults.

This suggests that although dormant cancer cells do not multiply rapidly or form detectable tumors, they are not necessarily sleeping. Instead, at times they might be actively communicating with each other and their microenvironment through the numerous proteins they manufacture.

Overall, this might be a clever way for dormant cancer cells to "fly under the radar" and, at the same time, modify their microenvironment, making it more suitable for them to grow in the future.

Can cell cannibalism be exploited for diagnosis and treatment?

Although our results are promising, it's important to be cautious. While there appears to be a strong correlation between cell cannibalism and dormancy, for now we do not know if it is directly linked to cancer recurrence in patients. Studies are underway, however, to corroborate our findings.

Still, the fact that breast cancer cells cannibalize MSCs is intriguing. It provides an important foundation for developing new diagnostic tools and therapies. Indeed, we currently have several ways of applying our recent discoveries.

One exciting idea is to exploit the cannibalistic activity of cancer cells to feed them suicide genes or other toxic agents, using MSCs as a delivery vehicle, like a tumor-seeking missile.

Importantly, MSCs can be easily obtained from the body, expanded to large numbers in the laboratory, and put back into the patient. Indeed, they have already been used safely in clinical trials to treat a variety of diseases due to their ability to aid in tissue repair and regeneration.

A different avenue for drug development would involve keeping dormant cells in a harmless and nondividing state forever. It might also be possible to prevent cancer cells from eating the stem cells in the first place.

In our study, we were able to block cell cannibalism using a drug that targets a specific protein inside cancer cells. With this treatment approach, the cancer might essentially starve to death or be more easily killed by conventional therapies.

Explore further: A possible explanation for recurring breast cancer

This article was originally published on The Conversation. Read the original article.

In October, we mourned those who died of breast cancer and celebrated all of the women (and men) who have survived. What many of those survivors worry about, though, is that their breast cancer may come back. It has puzzled ...

Researchers from Mayo Clinic have quantified the numbers of various types of immune cells associated with the risk of developing breast cancer. The findings are published in a study in Clinical Cancer Research.

To understand what makes breast cancer spread, researchers are looking at where it lives - not just its original home in the breast but its new home where it settles in other organs. What's happening in that metastatic niche ...

New research explains how metastatic breast cancer cells might use bone marrow-derived mesenchymal stem cells (MSCs) to help them spread to bone tissue. A study using a 3D scaffold model has shown that breast tumor-derived ...

Scientists from the United States have made an important step toward eliminating cancer recurrence by combining immunotherapy with chemotherapy. Specifically, they found that chemotherapy alone leads to two types of dormant ...

A new study has identified a mechanism used by tumors to recruit stem cells from bone and convert them into cancer-associated fibroblasts (CAFs) that facilitate tumor progression. This work, which pinpoints the specific biochemical ...

Research findings that first had scientists scratching their heads have turned out to be "quite revolutionary," according to study leaders at The Scripps Research Institute (TSRI).

For all the success of a new generation of immunotherapies for cancer, they often leave an entire branch of the immune system's disease-fighting forces untapped. Such therapies act on the adaptive immune system, the ranks ...

Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by multiple myeloma. The findings are published in Nature Medicine.

Doctors may soon be able to detect and monitor a patient's cancer with a simple blood test, reducing or eliminating the need for more invasive procedures, according to Purdue University research.

Two key proteins involved in male breast cancer have been identified by University of Leeds scientists, potentially paving the way for more effective treatments.

A protein has been found to have a previously unknown role in the ageing of cells, according to an early study by Queen Mary University of London (QMUL). The researchers hope that the findings could one day lead to new treatments ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the rest here:
How 'cannibalism' by breast cancer cells promotes dormancy: A possible clue into cancer recurrence - Medical Xpress

Read More...

Page 27«..1020..26272829..40..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick